Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

61. Coronary heart disease risk in patients with schizophrenia: a Lebanese cross-sectional study Full Text available with Trip Pro

Coronary heart disease risk in patients with schizophrenia: a Lebanese cross-sectional study Coronary heart disease (CHD) is a leading cause of premature death in patients with schizophrenia. CHD risk in Lebanese patients with schizophrenia remains unknown.To (i) evaluate CHD risk of patients with schizophrenia in Lebanon; and (ii) detect the modifiable and non-modifiable factors affecting this risk.Cross-sectional study of 329 patients with schizophrenia aged 20-75 years. Ten-year hard CHD (...) , confidence interval [CI] 1.54-4.64), a longer duration of schizophrenia (OR 1.03, CI 1.01-1.05), a history of other medical illnesses (OR 2.02, CI 1.18-3.47), and in those participating in art therapy (OR 2.13, CI 1.25-3.64) or therapeutic education (OR 1.93, CI 0.93-4.01). Ten-year hard CHD risk was lower in patients receiving risperidone (OR 0.23, CI 0.08-0.68), any anti-epileptic (OR 0.41, CI 0.24-0.73), or any benzodiazepine (OR 0.33, CI 0.17-0.66) medication.CHD is prevalent in patients

2017 Journal of comorbidity

62. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence Full Text available with Trip Pro

Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence Limited treatment responses in schizophrenia prompted the testing of combining an antipsychotic drug treatment with a second psychotropic medication. A comprehensive evaluation of the efficacy of multiple medication combinations is missing.To summarize and compare the meta-analytically determined efficacy (...) be recommended for patients with schizophrenia based on the current meta-analytic literature.

2017 EvidenceUpdates

63. Clozapine dose for schizophrenia. Full Text available with Trip Pro

Clozapine dose for schizophrenia. Schizophrenia and related disorders such as schizophreniform and schizoaffective disorder are serious mental illnesses characterised by profound disruptions in thinking and speech, emotional processes, behaviour and sense of self. Clozapine is useful in the treatment of schizophrenia and related disorders, particularly when other antipsychotic medications have failed. It improves positive symptoms (such as delusions and hallucinations) and negative symptoms (...) (such as withdrawal and poverty of speech). However, it is unclear what dose of clozapine is most effective with the least side effects.To compare the efficacy and tolerability of clozapine at different doses and to identify the optimal dose of clozapine in the treatment of schizophrenia, schizophreniform and schizoaffective disorders.We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (August 2011 and 8 December 2016).All relevant randomised controlled trials (RCTs), irrespective

2017 Cochrane

64. Lumateperone for acute exacerbations of psychosis in schizophrenia

Lumateperone for acute exacerbations of psychosis in schizophrenia Lumateperone for acute exacerbations of psychosis in schizophrenia | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs (...) are produced as required for our stakeholders. > > > Lumateperone for acute exacerbations of psychosis in schizophrenia Lumateperone for acute exacerbations of psychosis in schizophrenia May 2017 Lumateperone is a new, orally administered antipsychotic drug which alters levels of several chemicals in the brain including dopamine, serotonin and glutamate. Studies on lumateperone in people with schizophrenia experiencing an episode of severe symptoms suggest it may reduce symptoms with less side effects than

2017 NIHR Innovation Observatory

65. Increases in Intrinsic Thalamocortical Connectivity and Overall Cognition Following Cognitive Remediation in Chronic Schizophrenia Full Text available with Trip Pro

Increases in Intrinsic Thalamocortical Connectivity and Overall Cognition Following Cognitive Remediation in Chronic Schizophrenia Thalamic projections to the prefrontal cortex (PFC) are critical for cognition, and disruptions in these circuits are thought to underlie the pathophysiology of schizophrenia. Cognitive remediation (REM) is a behavioral intervention that holds promise for improving cognition and functioning in schizophrenia, however the extent to which it affects thalamo-prefrontal (...) connections has not been researched. This study sought to determine whether patients with schizophrenia who undergo a placebo-controlled trial of REM show increased functional connectivity between the thalamus and PFC, and whether these changes correspond to improvements in cognition.Twenty-six patients with chronic schizophrenia were randomized to either 48 hours (over 16 weeks) of a drill-and-practice working memory-focused REM or an active placebo condition. All participants underwent cognitive

2017 Biological psychiatry. Cognitive neuroscience and neuroimaging Controlled trial quality: uncertain

66. Impaired suppression of delay-period alpha and beta is associated with impaired working memory in schizophrenia Full Text available with Trip Pro

Impaired suppression of delay-period alpha and beta is associated with impaired working memory in schizophrenia Although people with schizophrenia (PSZ) frequently exhibit reduced working memory capacity relative to healthy comparison subjects (HCS), the mechanisms that underlie this impairment are not yet known. The present study aimed to assess one putative mechanism: impaired suppression of alpha and beta frequency bands during the delay period of a visual working memory task.The

2017 Biological psychiatry. Cognitive neuroscience and neuroimaging

67. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Full Text available with Trip Pro

Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels. For these people, a number of treatment strategies have emerged, including the prescription of a second anti-psychotic drug in combination with clozapine.To determine the clinical effects of various clozapine combination strategies with antipsychotic drugs in people (...) with treatment-resistant schizophrenia both in terms of efficacy and tolerability.We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (to 28 August 2015) and MEDLINE (November 2008). We checked the reference lists of all identified randomised controlled trials (RCT). For the first version of the review, we also contacted pharmaceutical companies to identify further trials.We included only RCTs recruiting people of both sexes, aged 18 years or more, with a diagnosis of treatment

2017 Cochrane

68. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. (Abstract)

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Although predominant negative symptoms of schizophrenia can be severe enough to cause persistent impairment, effective treatment options are lacking. We aimed to assess the new generation antipsychotic cariprazine in adult patients with predominant negative symptoms.In this randomised, double-blind, phase 3b trial, we enrolled (...) adults aged 18-65 years with long-term (>2 year), stable schizophrenia and predominant negative symptoms (>6 months) at 66 study centres (mainly hospitals and university clinics, with a small number of private practices) in 11 European countries. Patients were randomly assigned (1:1) by an interactive web response system to 26 weeks of monotherapy with fixed-dose oral cariprazine (3 mg, 4·5 mg [target dose], or 6 mg per day) or risperidone (3 mg, 4 mg [target dose], or 6 mg per day); previous

2017 Lancet Controlled trial quality: predicted high

69. Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T Full Text available with Trip Pro

Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T Examining neurometabolic abnormalities in critical brain areas in schizophrenia and major depressive disorder (MDD) may help guide future pharmacological interventions including glutamate-modulating treatments.To measure metabolite concentrations within the anterior cingulate cortex (ACC) and thalamus of people with schizophrenia and people with MDD.Spectra were acquired from 16 (...) volunteers with schizophrenia, 17 with MDD and 18 healthy controls using magnetic resonance spectroscopy on a 7 Tesla scanner.In the thalamus, there were lower glycine concentrations in the schizophrenia group relative to control (P=0.017) and MDD groups (P=0.012), and higher glutamine concentrations relative to healthy controls (P=0.009). In the thalamus and the ACC, the MDD group had lower myo-inositol concentrations than the control (P=0.014, P=0.009, respectively) and schizophrenia (P=0.004, P=0.002

2017 BJPsych open

70. The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disorders

The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disorders The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disorders | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search (...) Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disorders David J Castle, Cherrie A Galletly, Frances Dark, Verity Humberstone, Vera A Morgan, Eóin Killackey, Jayashri Kulkarni, Patrick McGorry, Olav Nielssen, Nga T Tran and Assen Jablensky Med J Aust 2017

2017 MJA Clinical Guidelines

71. Outcomes: Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings

Outcomes: Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings | Evidence-Based Mental Health We use cookies to improve our service (...) name or password? You are here Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings Article Text This article has a correction. Please see: Electronic pages Outcomes Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed

2017 Evidence-Based Mental Health

72. Pharmacological interventions: More ACTIONS needed to reach a consensus on adjunctive antidepressant therapy for negative symptoms of schizophrenia

Pharmacological interventions: More ACTIONS needed to reach a consensus on adjunctive antidepressant therapy for negative symptoms of schizophrenia More ACTIONS needed to reach a consensus on adjunctive antidepressant therapy for negative symptoms of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here More ACTIONS needed to reach a consensus on adjunctive antidepressant therapy for negative symptoms of schizophrenia

2017 Evidence-Based Mental Health

77. Necessity of oral health intervention in schizophrenic patients - A review Full Text available with Trip Pro

Necessity of oral health intervention in schizophrenic patients - A review Individuals with mental illness often cannot perform day to day activities due to a psychiatric or emotional disorder. Schizophrenia is one such psychiatric disorder characterized by worsening self-care ability with progressing mental illness. This disease may potentially deteriorate oral health by affecting the subject's ability to perform oral hygiene measures. Literature on oral disease manifestations in schizophrenia (...) is limited. Lack of desire for oral health care as well as generally poor awareness of oral health issues in these patients, compounded further by side effects of medications, may complicate dental management in schizophrenic patients. The present review explores clinical features and possible factors associated with oral health status among those with Schizophrenia.

2016 Nepal journal of epidemiology

78. 29 Year Old Man with Multiple Sclerosis and Schizophrenia: A Case Report Full Text available with Trip Pro

29 Year Old Man with Multiple Sclerosis and Schizophrenia: A Case Report Multiple sclerosis (MS) is the most common debilitating neurological disease that affects adults, whether young adults or middle-aged. Although, most attention is toward the neurological signs of the disease, the neuropsychiatric signs are not uncommon. This case report presents a 29 year old male with a record of obsessive-compulsive disorder (OCD) without psychotic disorder, which coincides with the diagnosis MS, has (...) of schizophrenia which was confirmed in subsequent visits. The signs of the patient were not controllable for a long time and finally fully controlled by a combination of Aripiprazole (abilizol), Risperidone and Sertraline, and currently, for almost 3 years, both psychotic symptoms and MS disease have been under control. Our patient seems to catch the MS disease and schizophrenia simultaneously. There was no relation between MS and psychosis episodes and the MS attacks. Since the onset the patient had several

2016 Electronic physician

79. Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report Full Text available with Trip Pro

Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report There is currently limited experience in the initiation and maintenance of clozapine for treatment-resistant psychosis in adults with established structural heart disease. These complex patients require close supervision and liaison between colleagues. Here we present the successful experience of treating one such patient within our service and describe a monitoring plan to ensure (...) that these treatments can be provided both safely and effectively.A 36-year-old man with treatment-resistant schizophrenia and known hypertrophic cardiomyopathy (HCM) was admitted to a specialist unit for a trial of clozapine. His psychiatric illness was characterised by multimodal hallucinations and delusions combined with low mood and poor motivation. The diagnosis of HCM was made 3 years previously following a routine electrocardiogram (ECG), and he had remained asymptomatic throughout this time; there were

2016 BJPsych open

80. Integrated supported employment plus cognitive remediation training for people with schizophrenia. (Abstract)

Integrated supported employment plus cognitive remediation training for people with schizophrenia. 26908337 2016 12 13 2016 12 30 1024-2708 22 Suppl 2 2016 Feb Hong Kong medical journal = Xianggang yi xue za zhi Hong Kong Med J Integrated supported employment plus cognitive remediation training for people with schizophrenia. S15-8 Tsang H W H HW Neuropsychiatric Rehabilitation Laboratory, Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong. Bell M D MD (...) methods Employment, Supported methods Executive Function Female Hong Kong Humans Male Middle Aged Psychiatric Status Rating Scales Schizophrenia rehabilitation Social Skills 2016 2 25 6 0 2016 2 26 6 0 2016 12 15 6 0 ppublish 26908337

2016 Hong Kong medical journal = Xianggang yi xue za zhi Controlled trial quality: uncertain